Oncology Medical News about gemcitabine efficacy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment
Expert Review of Anticancer Therapy, 10/26/09

Marechal R et al. – This study demonstrates that dCK protein concentration levels were regulated by HuR and that a high cytoplasmic HuR level was associated with a sevenfold decreased risk of mortality after resection of pancreatic adenocarcinoma and gemcitabine therapy.

<< Previous
Lapatinib monotherapy in patients with relapsed, advanced, or...

Next >>
Estrogen Receptor–Negative Breast Cancer: New Insights into...

Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer
Journal of Clinical Oncology, 11/05/09 Relevance Score: 68%

Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study
British Journal of Cancer, 11/18/09 Relevance Score: 67%

Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer
Journal of Clinical Oncology, 11/03/09 Relevance Score: 67%

Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance
Journal of Clinical Oncology, 10/26/09 Relevance Score: 65%

Feasibility study for biweekly administration of cisplatin plus gemcitabine as adjuvant-chemotherapy for completely resected non-small cell lung cancer
Cancer Chemotherapy and Pharmacology, 10/14/09 Relevance Score: 65%